Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma

ClinicalTrials.gov ID: NCT02054130

Public ClinicalTrials.gov record NCT02054130. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects With Inadequately Controlled, Severe Asthma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of the study is to evaluate the effect of 3 dose levels of MEDI9929 (AMG 157) on asthma exacerbations in adult subjects with inadequately controlled, severe asthma.

Study identification

NCT ID: NCT02054130
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: MedImmune LLC; Industry
Enrollment: 584 participants

Conditions and interventions

Conditions

Asthma

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 13, 2013 (Actual)
Primary completion: Dec 12, 2016 (Actual)
Completion: Mar 1, 2017 (Actual)
Last update posted: Dec 4, 2018

2013 – 2017

United States locations

U.S. sites: 18
U.S. states: 13
U.S. cities: 15

Facility	City	State	ZIP	Site status
Research Site	Los Angeles	California	90025	—
Research Site	Los Angeles	California	90048	—
Research Site	Miami	Florida	33133	—
Research Site	Oviedo	Florida	32765	—
Research Site	Savannah	Georgia	31406	—
Research Site	Peoria	Illinois	61602	—
Research Site	Baltimore	Maryland	21224	—
Research Site	Rochester	Minnesota	55905	—
Research Site	New York	New York	10016	—
Research Site	New York	New York	10029	—
Research Site	Charlotte	North Carolina	28207	—
Research Site	Charlotte	North Carolina	28277	—
Research Site	Dublin	Ohio	43016	—
Research Site	Oklahoma City	Oklahoma	73120	—
Research Site	Rock Hill	South Carolina	29732	—
Research Site	Spartanburg	South Carolina	29303	—
Research Site	Houston	Texas	77070	—
Research Site	Richmond	Virginia	23220	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 89 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02054130, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 4, 2018 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02054130 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →